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Oesophageal	 cancer	 remains	 a	 common	 cause	 of	 cancer	 mortality	 worldwide.	 Increasingly,	 oncology	
centres	are	treating	an	older	population	and	comorbidities	may	preclude	multimodality	treatment	with	
chemoradiotherapy.	 We	 review	 outcomes	 of	 radical	 radiotherapy	 in	 an	 older	 population	 treating	
Squamous	Cell	Carcinoma	(SCC)	oesophagus.	
Methods	
Patients	over	65	years	 receiving	 radiotherapy	 for	 SCC	oesophagus	between	2013-2016	 in	 the	West	of	
Scotland	 were	 identified.	 Kaplan-Meier	 and	 Cox-regression	 analysis	 were	 used	 to	 compare	 overall	
survival	 (OS)	 between	 patients	 treated	with	 radical	 radiotherapy	 (RT)	 and	 radical	 chemoradiotherapy	
(CRT).	
Results	
There	 were	 83	 patients	 over	 65	 years	 treated	 with	 either	 RT	 (n=21)	 or	 CRT	 (n=62).	 There	 was	 no	
significant	difference	 in	median	OS	between	CRT	versus	RT	 (26.8	months	vs	28.5	months,	p=0.92).	All	
patients	 receiving	 RT	 completed	 their	 treatment	 whereas	 11%	 of	 CRT	 patients	 did	 not	 complete	
treatment.		
Conclusion	
Survival	 in	 this	 non-trial	 older	 patient	 group	 managed	 with	 CRT	 is	 comparable	 to	 that	 reported	 in	



































Radiotherapy,	 with	 or	 without	 concurrent	 chemotherapy	 is	 an	 option	 for	 radical	 management	 in	
appropriate	 patients	 [1-3].	 With	 an	 aging	 population	 it	 is	 increasingly	 common	 to	 offer	 a	 radical	
approach	 to	 the	 older	 patient.	 Over	 40%	 of	 new	 cases	 are	 now	 patients	 aged	 75	 years	 or	 over	 [4].	
Squamous	cell	carcinoma	of	the	oesophagus	is	associated	with	risk	factors	such	as	smoking	and	alcohol	
and	 is	 less	 common	 than	 adenocarcinoma	 of	 the	 oesophagus	 which	 is	 increasing	 in	 incidence.	
Management	 between	 adenocarcinoma	 and	 squamous	 cell	 carcinoma	 of	 the	 oesophagus	 can	 differ.	
Non-surgical	treatment	with	radical	radiotherapy	or	chemoradiotherapy	 in	squamous	cell	carcinoma	is	
accepted	as	an	appropriate	treatment	strategy	[5-8].	Whilst	the	incidence	of	squamous	carcinoma	of	the	
oesophagus	has	been	declining	 in	 recent	 years,	 it	 remains	 an	 important	proportion	of	 the	population	
referred	for	treatment.	Worldwide,	SCC	still	accounts	for	90%	of	oesophageal	cancers	however	Western	
countries	 have	 shown	 decline	 in	 recent	 years	 such	 as	 in	 the	 USA.	 Between	 1975	 and	 2001	 SCC	




We	 report	 the	 experience	 of	 a	 large	 tertiary	 cancer	 centre	 treating	 squamous	 cell	 carcinoma	 of	 the	
oesophagus	with	radiotherapy	alone	as	an	alternative	 in	 those	patients	not	deemed	fit	 for	concurrent	
chemotherapy	or	where	 chemotherapy	 is	 contraindicated	due	 to	performance	 status,	 co-morbidity	or	




This	 was	 a	 retrospective	 review	 of	 patients	 with	 squamous	 cell	 carcinoma	 (SCC)	 who	 were	 radically	
treated	between	March	2013	and	March	2016	in	the	Beatson	West	of	Scotland	Cancer	Centre,	looking	at	
performance	status,	TNM	7	staging,	tumour	length	and	treatment	length	along	with	survival	of	patients	
[14].	 	 Patients	 underwent	 endoscopic	 ultrasound	 (EUS),	 Computed	 Tomography	 (CT)	 and	 Positron	
Emission	 Tomography	 (PET)	 as	 part	 of	 tumour	 staging.	 Data	 was	 collected	 using	 electronic	 patient	
records	and	appropriate	ethical	permissions	were	obtained.	Patients	were	analysed	on	an	 intention	to	
treat	basis	 (see	Figure	1).	Tumour	 length	was	measured	 from	ECLIPSE	 radiotherapy	planning	 software	
using	 the	 Gross	 Tumour	 Volume	 (GTV)	 from	 peer	 reviewed	 radiotherapy	 plans.	 All	 plans	 were	 peer-
















Radiotherapy	 in	 this	 centre	 is	 delivered	 using	 intensity-modulated	 radiotherapy	 (IMRT)	 and	 more	
recently	 volumetric	 modulated	 arc	 therapy	 (VMAT)	 which	 can	 allow	 for	 improved	 conformality	 of	
radiotherapy	 dose	 and	 lower	 dose	 to	 organs	 at	 risk	 (OARs).	 Planning	 for	 these	 patients	was	 a	mix	 of	
IMRT	 3	 and	 4	 field	 radiotherapy	 planning	 with	 migration	 to	 a	 primarily	 VMAT	 solution	 in	 2015.		
Radiotherapy	GTV	was	defined	using	 composite	 information	provided	 from	EUS,	 CT	 and	PET	 imaging.	




The	 characteristics	 of	 patients	 receiving	 radiotherapy	 or	 chemoradiotherapy	 were	 summarised	 using	




























	 	 	 	 	 	
	
Compliance	
Gender	 Male	 39	[47.0]	 32	[51.6]	 7	[33.3]	
	 Female	 44	[53.0]	 30	[48.4]	 14	[66.7]	
	
p=0.147	
	 	 	 	 	 	
ECOG	Performance	Status	(PS)	 	 	 	 	
- PS	0	 	 39	[47.0]	 32	[51.6]	 7	[33.3]	
- PS	1	 	 37	[44.6]	 29	[46.8]	 8	[38.1]	




	 	 	 	 	 	
Overall	Stage	TNM	8	 	 	 	 	
- Stage	I	 	 6	[7.2]	 5	[8.1]	 1	[4.8]	
- Stage	II	 	 45	[54.2]	 31	[50.0]	 14	[66.7]	
- Stage	III	 	 30	[36.14]	 24	[38.71]	 6	[28.57]	








5.7	(±3.01;	4.1-8.25)	 6.2(±3.28;	4.1-8.8)	 5.2	(±1.94;	4.1-6.5)	 p=0.281	
	 ≤6cm	 41	[49.4]	 29	[46.8]	 12	[57.1]	 	














was	 identified	based	upon	the	 length	stated	on	either	EUS,	endoscopy	or	 radiology	reports.	However,	
there	were	18	patients	that	did	not	have	a	recorded	length	based	upon	these	investigations.	The	main	
reason	for	the	missing	data	was	the	presence	of	impassable	disease	recorded	on	EUS	in	11	patients.	This	
resulted	 in	 the	 absence	 of	 a	 lower	 border	 being	 reported	 (CRT=9,	 RT=2).	 Therefore,	 GTV	 length	
identified	 on	 radiotherapy	 planning	 software	 was	 used	 as	 an	 alternative	 comparative	 marker	 to	





late	 stage	 cancers	 (stage	 I=	 37.3	months;	 95%CI	 35.5-na	 vs	 stage	 III=	 16.8	months;	 95%CI	 12.83-26.7;	
p=0.02,	see	Figure	2a).	However,	there	was	no	statistically	significant	difference	in	median	OS	between	
the	RT	 and	CRT	 group	 (RT	 28.5	months	 95%CI	 16.8-na,	 CRT	 26.7	months;	 95%CI	 18.4-na,	 p=0.79,	 see	
Figure	2b).	There	was	a	non-significant	increased	risk	of	death	in	the	male	population	vs	females	(Male:	
HR	 1.17;	 95%CI=0.66-2.10;	 p=0.574).	 Patients	 with	 GTV	 lengths	 of	 ≥6cm	 had	 a	 greater	 risk	 of	 death	
irrespective	of	treatment	modality	(HR	for	≥6cm-	1.86,	p=0.041,	see	Figure	2c,	Table	2).	Patients	with	a	












Unadjusted	HR	 95%	CI	 P-value	 Fully	adjusted	HR	 95%	CI	 	 P-value	
Female	 1	 	 	 1	 	 	 	
Male	 1.13	 0.65-1.96	 p=0.656	 1.17	 0.66-2.10	 	 p=0.574	
	 	 	 	 	 	 	 	
- PS	0	 1	 	 	 1	 	 	 	
- PS	≥1	 2.00	 1.14-3.53	 p=0.016	 2.11	 1.12-3.97	 	 p=0.020	
	 	 	 	 	 	 	 	
- Stage	I	 1	 	 	 1	 	 	 	
- Stage	II	 2.07	 0.49-8.79	 p=0.326	 1.55	 0.35-6.79	 	 p=0.563	
- Stage	III	 4.31	 1.01-18.35	 p=0.050	 3.18	 0.72-14.00	 	 p=0.126	
	 	 	 	 	 	 	 	
Radiotherapy	 1	 	 	 1	 	 	 	
Chemo-radiotherapy	 0.92	 0.50-1.71	 p=0.793	 0.88	 0.45-1.72	 	 p=0.708	
	 	 	 	 	 	 	 	
- GTV	<6cm	 1	 	 	 1	 	 	 	
									-								GTV	≥6cm	 1.96	 11.0-3.47	 p=0.021	 1.86	 1.03-3.37	 	 p=0.041	









In	 this	 retrospective	 study	 focussing	on	data	 from	2013-2016	 in	 the	Beatson	West	of	Scotland	Cancer	
Centre	we	 found	 that	most	 of	 the	 RT	 group	were	 over	 75	 years	 (80.9%)	 compared	 to	 a	 significantly	
younger	 CRT	 group	 (mean	 age=72.8	 years,	 percentage	 over	 75=33.9%,	 p=0.0001).	 The	 difference	 in	
survival	between	sexes	was	non-significant	although	trended	towards	an	increased	risk	of	death	in	the	
male	 population.	 This	 may	 warrant	 future	 investigation	 in	 the	 context	 of	 the	 higher	 percentage	 of	
females	in	the	RT	group.	Though	the	numbers	are	relatively	small,	this	higher	percentage	should	also	be	
considered	when	 looking	at	 the	 relatively	good	 survival	of	 the	RT	group	as	 improved	 survival	 in	older	
females	has	been	seen	in	other	cancers	such	in	lung	cancer	[16-19].	There	was	no	significant	difference	
in	 median	 OS	 between	 CRT	 and	 RT	 groups	 (Figure	 2b).	 Chemoradiotherapy	 median	 OS	 remains	
comparable	with	other	centres	and	the	SCOPE-1	data,	which	is	reassuring	on	considering	that	this	is	an	
older,	 real	 world	 -	 population	 [20-22].	 	 As	 expected,	 poorer	 performance	 status	 and	 longer	 tumours	
were	all	associated	with	poorer	survival.	
It	is	of	interest	that	as	part	of	this	retrospective	review	that	there	is	a	disparity	in	ages	between	the	CRT	
and	 RT	 group.	 Multiple	 clinical	 trials	 across	 numerous	 tumour	 types	 have	 demonstrated	 the	 risk	 of	
increased	 toxicity	 of	 combining	 chemotherapy	with	 radiotherapy	 [23-26].	 The	 stark	 difference	 in	 age	
between	RT	and	CRT	groups	may	arise	from	a	clinical	concern	about	fitness	for	multimodality	treatment	
as	 the	 older	 patient,	 whilst	 fit,	may	 be	 physiologically	 frailer	 than	 a	 younger	 individual.	 This	 is	 often	
gestalt	rather	than	based	on	objective	measures.	Geriatric	assessment	tools	are	an	emerging	field	that	
will	 be	 important	 in	 determining	 objective	 rather	 than	 subjective	 assessment	 for	 suitability	 of	
concurrent	treatment	 [27,	28].	Similarly,	 future	clinical	 trials	should	aim	to	 include	older	patients	with	
robust	 assessment	 tools	 particularly	 as	 this	 particular	 subgroup	 is	 often	 underrepresented	 but	 is	
increasing	 in	 clinical	 relevance	 [29].	 This	 represents	 a	 larger	 discussion	 that	 remains	 ongoing	 in	 the	
oncology	 community	when	 consider	 how	 to	 balance	 these	 issues	where	 older	 patients	 have	 radically	
treatable	cancers.		
The	 survival	 of	 patient	 undergoing	 single	 modality	 radiotherapy	 is	 perhaps	 surprising	 given	 the	




after	 28	 days.	 Survival	 in	 this	 review	 is	 comparable	 to	 other	 centres	 using	 hypofractionated	 single	
modality	 radiotherapy	 and	 shows	 favourable	 outcomes	 in	 this	 patient	 group	 [30].	 New	 treatment	
modalities	 such	 as	 VMAT	 allow	 for	 excellent	 dose	 homogeneity	 to	 tumours	 with	 effective	 tissue	
simulation	to	estimate	doses	to	primary	tumour	and	organs	at	risk.	Finally,	another	consideration	is	that	
this	 may	 also	 be	 an	 indication	 of	 appropriate	 patient	 selection	 and	 a	 pragmatic	 approach	 to	 frailer	
patients.	 It	 appears	 that	 single	 modality	 radiotherapy	 may	 be	 safe	 and	 deliverable	 in	 an	 older	
population.	
There	were	several	impassable	tumours	in	the	CRT	group	(n=9)	which	were	included	in	the	unrecorded	
tumour	 lengths.	Of	 the	11	patients	who	had	 confirmed	 impassable	 tumours	 there	were	no	 long-term	
survivors	after	3	years	of	follow	up.	This	may	suggest	that	an	impassable	tumour	on	EUS	or	endoscopy	is	




treatment	 in	 the	CRT	 group.	 	 All	 patients	 in	 the	RT	 group	 completed	 treatment	 compared	 to	 an	 11%	
non-completion	 in	the	CRT	group.	This	 is	comparable	to	non-completion	rate	 in	other	centres	and	the	
SCOPE-1	trial	which	was	around	10%	[13,	20,	22].	Palliative	locally	advanced	oesophageal	cancer	survival	
is	often	challenging	to	estimate	but	may	be	expected	to	be	between	6	to	9	months	though	not	usually	
over	 a	 year	 [31].	 The	 survival	 of	 RT	 patients	 in	 this	 review	 certainly	 appears	 favourable	 compared	 to	
these	palliative	patients	however	the	heterogeneity	in	these	groups	prevents	direct	comparison.			
The	major	 limitation	 is	 the	 retrospective	nature	of	 the	 study.	 Though	 this	 information	 can	be	applied	
more	 generally,	 the	 lack	 of	 prospective	 fitness	 assessment	 in	 fitness	 prohibits	 a	 more	 detailed	
assessment	of	this	population’s	characteristics.	Performance	status	is	a	relatively	limited	descriptor	and	
does	 not	 holistically	 represent	 true	 patient	 fitness	 [27].	 Future	 prospective	 reviews	 should	 utilise	
comprehensive	 geriatric	 assessment	 tools	 which	 give	 fuller	 assessments	 of	 this	 population	 as	 these	




that	 we	 have	 used	 GTV	 rather	 than	 prospectively	 gathered	 data	 from	 EUS,	 PET	 and	 CT	 to	 estimate	







for	 chemoradiotherapy.	 Chemoradiotherapy	 should	 remain	 a	 standard	of	 care	 in	 radical	 treatment	 of	
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